Targeting Toll-like receptors: emerging therapeutics?

Key Points

  • Toll-like receptors (TLRs) and their signalling pathways have therapeutic potential for the treatment of inflammation, cancer, infection, allergy and autoimmunity.

  • The elucidation of the structure of several TLRs may aid medicinal chemistry in the rational design of small-molecule agonists and antagonists.

  • Agonists for TLR4, TLR7, TLR8 and TLR9 are being tested as adjuvants for infectious diseases and in certain cancers. There is also potential for some of these agents in the de-sensitization of airways in allergic asthma and allergy.

  • TLR antagonists are being investigated for the treatment of inflammatory diseases. Examples here include the inhibition of TLR7 and TLR9 in systemic lupus erythematosus, inhibition of TLR4 in sepsis and asthma or allergy, and inhibition of TLR2 in ischaemia and reperfusion injury.

  • Emerging findings on the underlying mechanism of TLR action might also lend themselves to therapeutic manipulation. Examples here include modulation of microRNAs, the exploitation of viral proteins to prevent nuclear factor-κB signalling and the development of compounds that interfere with the ubiquitination of signalling molecules.

Abstract

There is a growing interest in the targeting of Toll-like receptors (TLRs) for the prevention and treatment of cancer, rheumatoid arthritis, inflammatory bowel disease and systemic lupus erythematosus (SLE). Several new compounds are now undergoing preclinical and clinical evaluation, with a particular focus on TLR7 and TLR9 activators as adjuvants in infection and cancer, and inhibitors of TLR2, TLR4, TLR7 and TLR9 for the treatment of sepsis and inflammatory diseases. Here, we focus on TLRs that hold the most promise for drug discovery research, highlighting agents that are in the discovery phase and in clinical trials, and on the emerging new aspects of TLR-mediated signalling — such as control by ubiquitination and regulation by microRNAs — that might offer further possibilities of therapeutic manipulation.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Figure 1: TLR1, TLR2, TLR3 and TLR4 molecular structures and signalling pathways.
Figure 2: Detailed interactions between LPS, MD-2 and TLR4.
Figure 3: Examples of small-molecule TLR agonist or antagonist structures.
Figure 4: New potential targets in TLR signalling.
Figure 5: Molecules involved in TLR signalling that when inhibited could have an effect on the inflammatory response.

References

  1. 1

    O'Neill, L. Targeting signal transduction as a strategy to treat inflammatory diseases. Nature Rev. Drug Discov. 5, 549–563 (2006).

  2. 2

    Koropatnick, T. A. et al. Microbial factor-mediated development in a host–bacterial mutualism. Science 306, 1186–1188 (2004).

  3. 3

    Park, B. S. et al. The structural basis of lipopolysaccharide recognition by the TLR4–MD-2 complex. Nature 458, 1191–1195 (2009). References 3, 6 and 7 are the first studies to illustrate the crystal structures for TLR4, TLR3 and the TLR1–TLR2 heterodimer with their specific ligands.

  4. 4

    Dziarski, R. & Gupta, D. Role of MD-2 in TLR2- and TLR4-mediated recognition of Gram-negative and Gram-positive bacteria and activation of chemokine genes. J. Endotoxin Res. 6, 401–405 (2000).

  5. 5

    Carpenter, S. & O'Neill, L. A. Recent insights into the structure of Toll-like receptors and post-translational modifications of their associated signalling proteins. Biochem. J. 422, 1–10 (2009).

  6. 6

    Liu, L. et al. Structural basis of toll-like receptor 3 signaling with double-stranded RNA. Science 320, 379–381 (2008).

  7. 7

    Jin, M. S. et al. Crystal structure of the TLR1–TLR2 heterodimer induced by binding of a tri-acylated lipopeptide. Cell 130, 1071–1082 (2007).

  8. 8

    Kawai, T. & Akira, S. TLR signaling. Cell Death Differ. 13, 816–825 (2006).

  9. 9

    Somani, N. & Rivers, J. K. Imiquimod 5% cream for the treatment of actinic keratoses. Skin Therapy Lett. 10, 1–6 (2005).

  10. 10

    Stockfleth, E., Christophers, E., Benninghoff, B. & Sterry, W. Low incidence of new actinic keratoses after topical 5% imiquimod cream treatment: a long-term follow-up study. Arch. Dermatol. 140, 1542 (2004).

  11. 11

    Larange, A., Antonios, D., Pallardy, M. & Kerdine-Romer, S. TLR7 and TLR8 agonists trigger different signaling pathways for human dendritic cell maturation. J. Leukoc. Biol. 85, 673–683 (2009).

  12. 12

    Lysa, B. et al. Gene expression in actinic keratoses: pharmacological modulation by imiquimod. Br. J. Dermatol. 151, 1150–1159 (2004).

  13. 13

    Schwartz, D. & Cook, D. Polymorphisms of the Toll-like receptors and human disease. Clin. Infect. Dis. 41 (Suppl. 7), 403–407 (2005).

  14. 14

    Ishii, K. J. & Akira, S. Toll or toll-free adjuvant path toward the optimal vaccine development. J. Clin. Immunol. 27, 363–371 (2007).

  15. 15

    Ehlers, M. & Ravetch, J. V. Opposing effects of Toll-like receptor stimulation induce autoimmunity or tolerance. Trends Immunol. 28, 74–79 (2007).

  16. 16

    Meneghin, A. & Hogaboam, C. M. Infectious disease, the innate immune response, and fibrosis. J. Clin. Invest. 117, 530–538 (2007).

  17. 17

    Rakoff-Nahoum, S. & Medzhitov, R. Toll-like receptors and cancer. Nature Rev. Cancer 9, 57–63 (2009).

  18. 18

    Cho, Y. J., Ahn, B. Y., Lee, N. G., Lee, D. H. & Kim, D. S. A combination of E. coli DNA fragments and modified lipopolysaccharides as a cancer immunotherapy. Vaccine 24, 5862–5871 (2006).

  19. 19

    Wei, M. Q., Mengesha, A., Good, D. & Anne, J. Bacterial targeted tumour therapy — dawn of a new era. Cancer Lett. 259, 16–27 (2008).

  20. 20

    Hemmi, H. et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nature Immunol. 3, 196–200 (2002).

  21. 21

    O'Neill, L. A., Bryant, C. E. & Doyle, S. L. Therapeutic targeting of toll-like receptors for infectious and inflammatory diseases and cancer. Pharmacol. Rev. 61, 177–197 (2009).

  22. 22

    Lan, T. et al. Stabilized immune modulatory RNA compounds as agonists of Toll-like receptors 7 and 8. Proc. Natl Acad. Sci. USA 104, 13750–13755 (2007).

  23. 23

    Dudek, A. Z. et al. First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer. Clin. Cancer Res. 13, 7119–7125 (2007).

  24. 24

    Dummer, R. et al. An exploratory study of systemic administration of the toll-like receptor-7 agonist 852A in patients with refractory metastatic melanoma. Clin. Cancer Res. 14, 856–864 (2008).

  25. 25

    Harrison, L. I., Astry, C., Kumar, S. & Yunis, C. Pharmacokinetics of 852A, an imidazoquinoline Toll-like receptor 7-specific agonist, following intravenous, subcutaneous, and oral administrations in humans. J. Clin. Pharmacol. 47, 962–969 (2007).

  26. 26

    Agrawal, S. & Kandimalla, E. R. Synthetic agonists of Toll-like receptors 7, 8 and 9. Biochem. Soc. Trans. 35, 1461–1467 (2007).

  27. 27

    Goodchild, A. et al. Primary leukocyte screens for innate immune agonists. J. Biomol. Screen 14, 723–730 (2009).

  28. 28

    Krieg, A. M. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 27, 161–167 (2008).

  29. 29

    Kochling, J. et al. Anti-tumor effect of DNA-based vaccination and dSLIM immunomodulatory molecules in mice with Ph+ acute lymphoblastic leukaemia. Vaccine 26, 4669–4675 (2008).

  30. 30

    Vollmer, J. et al. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur. J. Immunol. 34, 251–262 (2004).

  31. 31

    Dorn, A. & Kippenberger, S. Clinical application of CpG-, non-CpG-, and antisense oligodeoxynucleotides as immunomodulators. Curr. Opin. Mol. Ther. 10, 10–20 (2008).

  32. 32

    Schmidt, C. Clinical setbacks for toll-like receptor 9 agonists in cancer. Nature Biotech. 25, 825–826 (2007).

  33. 33

    Salaun, B., Coste, I., Rissoan, M. C., Lebecque, S. J. & Renno, T. TLR3 can directly trigger apoptosis in human cancer cells. J. Immunol. 176, 4894–4901 (2006).

  34. 34

    Panter G., K. A., Jerala R. Therapeutic applications of nucleic acids as ligands for Toll-like receptors. Curr. Opin. Mol. Ther. 11, 133–145 (2009).

  35. 35

    D'Agostini, C. et al. Antitumour effect of OM-174 and cyclophosphamide on murine B16 melanoma in different experimental conditions. Int. Immunopharmacol. 5, 1205–1212 (2005).

  36. 36

    Garay, R. P. et al. Cancer relapse under chemotherapy: why TLR2/4 receptor agonists can help. Eur. J. Pharmacol. 563, 1–17 (2007).

  37. 37

    De Ridder, M. et al. The radiosensitizing effect of immunoadjuvant OM-174 requires cooperation between immune and tumor cells through interferon-γ and inducible nitric oxide synthase. Int. J. Radiat. Oncol. Biol. Phys. 66, 1473–1480 (2006).

  38. 38

    Apetoh, L. et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nature Med. 13, 1050–1059 (2007).

  39. 39

    Simons, M. P., O'Donnell, M. A. & Griffith, T. S. Role of neutrophils in BCG immunotherapy for bladder cancer. Urol. Oncol. 26, 341–345 (2008).

  40. 40

    Murata, M. Activation of Toll-like receptor 2 by a novel preparation of cell wall skeleton from Mycobacterium bovis BCG Tokyo (SMP-105) sufficiently enhances immune responses against tumors. Cancer Sci. 99, 1435–1440 (2008).

  41. 41

    Burdelya, L. G. et al. An agonist of toll-like receptor 5 has radioprotective activity in mouse and primate models. Science 320, 226–230 (2008).

  42. 42

    Sfondrini, L. et al. Antitumor activity of the TLR-5 ligand flagellin in mouse models of cancer. J. Immunol. 176, 6624–6630 (2006).

  43. 43

    Parkinson, T. The future of toll-like receptor therapeutics. Curr. Opin. Mol. Ther. 10, 21–31 (2008).

  44. 44

    Schalm, S. W. et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J. Hepatol. 26, 961–966 (1997).

  45. 45

    Mark, K. E. et al. Topical resiquimod 0.01% gel decreases herpes simplex virus type 2 genital shedding: a randomized, controlled trial. J. Infect. Dis. 195, 1324–1331 (2007).

  46. 46

    Pockros, P. J. et al. Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies. J. Hepatol. 47, 174–182 (2007).

  47. 47

    Caron, G. et al. Direct stimulation of human T cells via TLR5 and TLR7/8: flagellin and R-848 up-regulate proliferation and IFN-γ production by memory CD4+ T cells. J. Immunol. 175, 1551–1557 (2005).

  48. 48

    Kronenberger, B. & Zeuzem, S. Current and future treatment options for HCV. Ann. Hepatol. 8, 103–112 (2009).

  49. 49

    Barry, M. & Cooper, C. Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy. Expert Opin. Biol. Ther. 7, 1731–1737 (2007).

  50. 50

    Harandi, A. M., Davies, G. & Olesen, O. F. Vaccine adjuvants: scientific challenges and strategic initiatives. Expert Rev. Vaccines 8, 293–298 (2009).

  51. 51

    Gu, M., Hine, P. M., James Jackson, W., Giri, L. & Nabors, G. S. Increased potency of BioThrax anthrax vaccine with the addition of the C-class CpG oligonucleotide adjuvant CPG 10109. Vaccine 25, 526–534 (2007).

  52. 52

    Krieg, A. M. Toll-free vaccines? Nature Biotech. 25, 303–305 (2007).

  53. 53

    Mata-Haro, V. et al. The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science 316, 1628–1632 (2007). This study showed that the vaccine adjuvant MPLA has a bias towards TRIF-dependent signalling, which has important implications for the development of future therapies.

  54. 54

    Gavin, A. L. et al. Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science 314, 1936–1938 (2006).

  55. 55

    van Duin, D., Medzhitov, R. & Shaw, A. C. Triggering TLR signaling in vaccination. Trends Immunol. 27, 49–55 (2006).

  56. 56

    Jasani, B., Navabi, H. & Adams, M. Ampligen: a potential toll-like 3 receptor adjuvant for immunotherapy of cancer. Vaccine 27, 3401–3404 (2009).

  57. 57

    Navabi, H. et al. A clinical grade poly I:C-analogue (Ampligen) promotes optimal DC maturation and Th1-type T cell responses of healthy donors and cancer patients in vitro. Vaccine 27, 107–115 (2009). A poly I:C analogue which stimulates dendritic cell maturation and IL-12 and induces much lower levels of IL-10 compared with poly I:C, has shown great promise as an adjuvant for cancer therapies.

  58. 58

    Huleatt, J. W. et al. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. Vaccine 26, 201–214 (2008). This study showed that the use of a TLR-specific ligand coupled to an influenza protein can offer widespread protection against strains of influenza A.

  59. 59

    Kanzler, H., Barrat, F. J., Hessel, E. M. & Coffman, R. L. Therapeutic targeting of innate immunity with Toll-like receptor agonists and antagonists. Nature Med. 13, 552–559 (2007).

  60. 60

    Gangloff, S. C. & Guenounou, M. Toll-like receptors and immune response in allergic disease. Clin. Rev. Allergy Immunol. 26, 115–125 (2004).

  61. 61

    Kline, J. N. & Krieg, A. M. Toll-like receptor 9 activation with CpG oligodeoxynucleotides for asthma therapy. Drug News Perspect. 21, 434–439 (2008).

  62. 62

    Heijink, I. H. & Van Oosterhout, A. J. Strategies for targeting T-cells in allergic diseases and asthma. Pharmacol. Ther. 112, 489–500 (2006).

  63. 63

    Pastorelli, L., Pizarro, T. T., Cominelli, F. & Vecchi, M. Emerging drugs for the treatment of ulcerative colitis. Expert Opin. Emerg. Drugs 14, 505–521 (2009).

  64. 64

    Baldrick, P., Richardson, D., Woroniecki, S. R. & Lees, B. Pollinex Quattro Ragweed: safety evaluation of a new allergy vaccine adjuvanted with monophosphoryl lipid A (MPL) for the treatment of ragweed pollen allergy. J. Appl. Toxicol. 27, 399–409 (2007).

  65. 65

    DuBuske L. M., C. M.a.H. T. Significant reduction in combined symptom and medication score compared with placebo following MPL-adjuvanted uSCIT in patients with seasonal grass pollen allergy. J. of Allergy Clin. Immunol. 123, S216–S216 (2009).

  66. 66

    Feldmann, M. Translating molecular insights in autoimmunity into effective therapy. Annu. Rev. Immunol. 27, 1–27 (2009).

  67. 67

    Klareskog, L. et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet 363, 675–681 (2004).

  68. 68

    van der Heijde, D. et al. Inhibition of radiographic progression with combination etanercept and methotrexate in patients with moderately active rheumatoid arthritis previously treated with monotherapy. Ann. Rheum. Dis. 68, 1113–1118 (2009). This study demonstrates that the use of a combination therapy consisting of the antiTNF drug etanercept and methotrexate is much more efficacious in treating patients with moderate rheumatoid arthritis than either therapy alone.

  69. 69

    Macfarlane, D. E. & Manzel, L. Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds. J. Immunol. 160, 1122–1131 (1998).

  70. 70

    Sun, S., Rao, N. L., Venable, J., Thurmond, R. & Karlsson, L. TLR7/9 antagonists as therapeutics for immune-mediated inflammatory disorders. Inflamm. Allergy Drug Targets 6, 223–235 (2007).

  71. 71

    Lipford G. et al. Selective Toll-like receptor 7/8/9 antagonists for the oral treatment of autoimmune diseases. American College of Rheumatology 2007 Annual Scientific Meeting (2007). ACR website [online], (2007).

  72. 72

    Barrat, F. J., Meeker, T., Chan, J. H., Guiducci, C. & Coffman, R. L. Treatment of lupus-prone mice with a dual inhibitor of TLR7 and TLR9 leads to reduction of autoantibody production and amelioration of disease symptoms. Eur. J. Immunol. 37, 3582–3586 (2007). This study showed that in plasmacytoid dendritic cells isolated from patients with SLE, the TLR7 and TLR9 inhibitor IRS954 inhibited the production of IFNα in response to DNA and RNA from viruses. The compound prevented disease progression in SLE-prone mice.

  73. 73

    Pawar, R. D. et al. Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus. J. Am. Soc. Nephrol. 18, 1721–1731 (2007).

  74. 74

    Jiang, W., Bhagat, L., Yu, D., Kandimalla, E. R. & Agrawal, S. IMO-3100, an antagonist of Toll-like receptors 7 and 9, modulates gene expression and regulatory networks induced by ligands. J. Immunol. 182, 48.25 (2009).

  75. 75

    Mullarkey, M. et al. Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist. J. Pharmacol. Exp. Ther. 304, 1093–1102 (2003).

  76. 76

    Savov, J. D. et al. Toll-like receptor 4 antagonist (E5564) prevents the chronic airway response to inhaled lipopolysaccharide. Am. J. Physiol. Lung Cell. Mol. Physiol. 289, L329–L337 (2005).

  77. 77

    Czeslick, E., Struppert, A., Simm, A. & Sablotzki, A. E5564 (Eritoran) inhibits lipopolysaccharide-induced cytokine production in human blood monocytes. Inflamm. Res. 55, 511–515 (2006).

  78. 78

    Bennett-Guerrero, E. et al. A phase II, double-blind, placebo-controlled, ascending-dose study of Eritoran (E5564), a lipid A antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass. Anesth. Analg. 104, 378–383 (2007).

  79. 79

    Wasan, K. M. et al. Influence of plasma cholesterol and triglyceride concentrations and eritoran (E5564) micelle size on its plasma pharmacokinetics and ex vivo activity following single intravenous bolus dose into healthy female rabbits. Pharm. Res. 25, 176–182 (2008).

  80. 80

    Cluff, C. W. et al. Synthetic toll-like receptor 4 agonists stimulate innate resistance to infectious challenge. Infect. Immun. 73, 3044–3052 (2005).

  81. 81

    Amlie-Lefond, C. et al. Innate immunity for biodefense: a strategy whose time has come. J. Allergy Clin. Immunol. 116, 1334–1342 (2005).

  82. 82

    Ulevitch, R. J. Therapeutics targeting the innate immune system. Nature Rev. Immunol. 4, 512–520 (2004).

  83. 83

    Ii, M. et al. A novel cyclohexene derivative, ethyl (6R)-6-[N-(2-Chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate (TAK-242), selectively inhibits toll-like receptor 4-mediated cytokine production through suppression of intracellular signaling. Mol. Pharmacol. 69, 1288–1295 (2006).

  84. 84

    Ledeboer, A. et al. The glial modulatory drug AV411 attenuates mechanical allodynia in rat models of neuropathic pain. Neuron Glia Biol. 2, 279–291 (2006).

  85. 85

    Ledeboer, A., Hutchinson, M. R., Watkins, L. R. & Johnson, K. W. Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes. Expert Opin. Investig. Drugs 16, 935–950 (2007).

  86. 86

    Ungaro, R. et al. A novel toll-like receptor 4 (TLR4) antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis. Am. J. Physiol. Gastrointest Liver Physiol. 296, G1167–G1179 (2009).

  87. 87

    Dunn-Siegrist, I. et al. Pivotal involvement of Fcγ receptor IIA in the neutralization of lipopolysaccharide signaling via a potent novel anti-TLR4 monoclonal antibody 15C1. J. Biol. Chem. 282, 34817–34827 (2007).

  88. 88

    Chen, K. et al. Toll-like receptors in inflammation, infection and cancer. Int. Immunopharmacol. 7, 1271–1285 (2007).

  89. 89

    Urbonaviciute, V. et al. Induction of inflammatory and immune responses by HMGB1-nucleosome complexes: implications for the pathogenesis of SLE. J. Exp. Med. 205, 3007–3018 (2008).

  90. 90

    Arslan, F., de Kleijn, D. P., Timmers, L., Doevendans, P. A. & Pasterkamp, G. Bridging innate immunity and myocardial ischemia/reperfusion injury: the search for therapeutic targets. Curr. Pharm. Des 14, 1205–1216 (2008).

  91. 91

    Chong, A. J. et al. Toll-like receptor 4 mediates ischemia/reperfusion injury of the heart. J. Thorac. Cardiovasc. Surg. 128, 170–179 (2004).

  92. 92

    Hua, F. et al. Differential roles of TLR2 and TLR4 in acute focal cerebral ischemia/reperfusion injury in mice. Brain Res. 1262, 100–108 (2009).

  93. 93

    Tang, S. C. et al. Pivotal role for neuronal Toll-like receptors in ischemic brain injury and functional deficits. Proc. Natl Acad. Sci. USA 104, 13798–13803 (2007).

  94. 94

    Chang, Y. C., Kao, W. C., Wang, W. Y., Yang, R. B. & Peck, K. Identification and characterization of oligonucleotides that inhibit Toll-like receptor 2-associated immune responses. FASEB J. 23, 3078–3088 (2009). This paper shows the development of a novel technique for identifying antagonistic TLR2 aptamers. Functional peptides were identified using a NF-κB reporter assay. One of the identified molecules reduced NF-κB by 80%.

  95. 95

    Sheedy, F. J. & O'Neill, L. A. Adding fuel to fire: microRNAs as a new class of mediators of inflammation. Ann. Rheum. Dis. 67 (Suppl. 3), 50–55 (2008).

  96. 96

    Taganov, K. D., Boldin, M. P., Chang, K. J. & Baltimore, D. NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc. Natl Acad. Sci. USA 103, 12481–12486 (2006). This is the first study to show a miRNA can have a direct role on NF-κB signalling through the targeting of IRAK1 and TRAF6.

  97. 97

    O'Connell, R. M., Chaudhuri, A. A., Rao, D. S. & Baltimore, D. Inositol phosphatase SHIP1 is a primary target of miR-155. Proc. Natl Acad. Sci. USA 106, 7113–7118 (2009).

  98. 98

    Tili, E. et al. Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-α stimulation and their possible roles in regulating the response to endotoxin shock. J. Immunol. 179, 5082–5089 (2007).

  99. 99

    Harte, M. T. et al. The poxvirus protein A52R targets Toll-like receptor signaling complexes to suppress host defense. J. Exp. Med. 197, 343–351 (2003).

  100. 100

    McCoy, S. L., Kurtz, S. E., Macarthur, C. J., Trune, D. R. & Hefeneider, S. H. Identification of a peptide derived from vaccinia virus A52R protein that inhibits cytokine secretion in response to TLR-dependent signaling and reduces in vivo bacterial-induced inflammation. J. Immunol. 174, 3006–3014 (2005).

  101. 101

    Tsung, A. et al. A novel inhibitory peptide of Toll-like receptor signaling limits lipopolysaccharide-induced production of inflammatory mediators and enhances survival in mice. Shock 27, 364–369 (2007).

  102. 102

    Buckley, G. M. et al. IRAK-4 inhibitors. Part III: a series of imidazo[1,2-a]pyridines. Bioorg Med. Chem. Lett. 18, 3656–3660 (2008).

  103. 103

    Cohen, P. Targeting protein kinases for the development of anti-inflammatory drugs. Curr. Opin. Cell Biol. 21, 317–324 (2009).

  104. 104

    Koziczak-Holbro, M. et al. The critical role of kinase activity of interleukin-1 receptor-associated kinase 4 in animal models of joint inflammation. Arthritis Rheum. 60, 1661–1671 (2009).

  105. 105

    Kawagoe, T. et al. Sequential control of Toll-like receptor-dependent responses by IRAK1 and IRAK2. Nature Immunol. 9, 684–691 (2008).

  106. 106

    Nalepa, G., Rolfe, M. & Harper, J. W. Drug discovery in the ubiquitin-proteasome system. Nature Rev. Drug Discov. 5, 596–613 (2006).

  107. 107

    Guedat, P. & Colland, F. Patented small molecule inhibitors in the ubiquitin proteasome system. BMC Biochem. 8 (Suppl. 1), S14 (2007).

  108. 108

    Cossu, F. et al. Structural basis for bivalent smac-mimetics recognition in the IAP protein family. J. Mol. Biol. 392, 630–644 (2009).

  109. 109

    Cossu, F. et al. Designing Smac-mimetics as antagonists of XIAP, cIAP1, and cIAP2. Biochem. Biophys. Res. Commun. 378, 162–167 (2009).

  110. 110

    Vince, J. E. et al. IAP antagonists target cIAP1 to induce TNFα-dependent apoptosis. Cell 131, 682–693 (2007). One of the first studies to show that IAP antagonists or SMAC mimetics could induce apoptosis of cancer cells by stimulating NF-κB and TNFα.

  111. 111

    Vallabhapurapu, S. et al. Nonredundant and complementary functions of TRAF2 and TRAF3 in a ubiquitination cascade that activates NIK-dependent alternative NF-kappaB signaling. Nature Immunol. 9, 1364–1370 (2008). This paper describes an alternative NF-κB activation pathway that involves an inhibitor of TLR signalling, TRAF2.

  112. 112

    Latz, E. et al. Lipopolysaccharide rapidly traffics to and from the Golgi apparatus with the toll-like receptor 4-MD-2–CD14 complex in a process that is distinct from the initiation of signal transduction. J. Biol. Chem. 277, 47834–47843 (2002).

  113. 113

    Hughes, A. L. & Piontkivska, H. Functional diversification of the toll-like receptor gene family. Immunogenetics 60, 249–256 (2008).

  114. 114

    Underhill, D. et al. The Toll-like receptor 2 is recruited to macrophage phagosomes and discriminates between pathogens. Nature 401, 811–815 (1999).

  115. 115

    Medzhitov, R. & Janeway, C. J. The Toll receptor family and microbial recognition. Trends Microbiol. 8, 452–456 (2000).

  116. 116

    Muzio, M. et al. Differential expression and regulation of toll-like receptors (TLR) in human leukocytes: selective expression of TLR3 in dendritic cells. J. Immunol. 164, 5998–6004 (2000).

  117. 117

    Zarember, K. A. & Godowski, P. J. Tissue expression of human Toll-like receptors and differential regulation of Toll-like receptor mRNAs in leukocytes in response to microbes, their products, and cytokines. J. Immunol. 168, 554–561 (2002).

  118. 118

    Strandskog, G., Ellingsen, T. & Jorgensen, J. B. Characterization of three distinct CpG oligonucleotide classes which differ in ability to induce IFN α/β activity and cell proliferation in Atlantic salmon (Salmo salar L.) leukocytes. Dev. Comp. Immunol. 31, 39–51 (2007).

  119. 119

    Geddes, K., Magalhaes, J. G. & Girardin, S. E. Unleashing the therapeutic potential of NOD-like receptors. Nature Rev. Drug Discov. 8, 465–479 (2009).

  120. 120

    Proell, M., Riedl, S. J., Fritz, J. H., Rojas, A. M. & Schwarzenbacher, R. The Nod-like receptor (NLR) family: a tale of similarities and differences. PLoS ONE 3, e2119 (2008).

  121. 121

    Fernandes-Alnemri, T., Yu, J. W., Datta, P., Wu, J. & Alnemri, E. S. AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA. Nature 458, 509–513 (2009).

  122. 122

    Koizumi, K. et al. Single nucleotide polymorphisms in the gene encoding the major histocompatibility complex class II transactivator (CIITA) in systemic lupus erythematosus. Ann. Rheum. Dis. 64, 947–950 (2005).

  123. 123

    Macaluso, F. et al. Polymorphisms in NACHT-LRR (NLR) genes in atopic dermatitis. Exp. Dermatol. 16, 692–698 (2007).

  124. 124

    Magitta, N. F. et al. A coding polymorphism in NALP1 confers risk for autoimmune Addison's disease and type 1 diabetes. Genes Immun. 10, 120–124 (2009).

  125. 125

    McGovern, D. P. et al. Association between a complex insertion/deletion polymorphism in NOD1 (CARD4) and susceptibility to inflammatory bowel disease. Hum. Mol. Genet. 14, 1245–1250 (2005).

  126. 126

    Skinningsrud, B. et al. Polymorphisms in CLEC16A and CIITA at 16p13 are associated with primary adrenal insufficiency. J. Clin. Endocrinol. Metab. 93, 3310–3317 (2008).

  127. 127

    Weidinger, S. et al. Association of NOD1 polymorphisms with atopic eczema and related phenotypes. J. Allergy Clin. Immunol. 116, 177–184 (2005).

  128. 128

    Noguchi, E., Homma, Y., Kang, X., Netea, M. G. & Ma, X. A Crohn's disease-associated NOD2 mutation suppresses transcription of human IL10 by inhibiting activity of the nuclear ribonucleoprotein hnRNP-A1. Nature Immunol. 10, 471–479 (2009).

  129. 129

    Ogura, Y. et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature 411, 603–606 (2001).

  130. 130

    Maksimovic, L. et al. New CIAS1 mutation and anakinra efficacy in overlapping of Muckle-Wells and familial cold autoinflammatory syndromes. Rheumatology 47, 309–310 (2008).

  131. 131

    Zapata, J. M. et al. Lymphocyte-specific TRAF3 transgenic mice have enhanced humoral responses and develop plasmacytosis, autoimmunity, inflammation, and cancer. Blood 113, 4595–4603 (2009).

  132. 132

    Bochud, P. Y. et al. Toll-like receptor 2 (TLR2) polymorphisms are associated with reversal reaction in leprosy. J. Infect. Dis. 197, 253–261 (2008).

  133. 133

    Thuong, N. T. et al. A polymorphism in human TLR2 is associated with increased susceptibility to tuberculous meningitis. Genes Immun. 8, 422–428 (2007).

  134. 134

    Lorenz, E., Mira, J., Cornish, K., Arbour, N. & Schwartz, D. A novel polymorphism in the toll-like receptor 2 gene and its potential association with staphylococcal infection. Infect. Immun. 68, 6398–6401 (2000).

  135. 135

    Agnese, D. et al. Human toll-like receptor 4 mutations but not CD14 polymorphisms are associated with an increased risk of Gram-negative infections. J. Infect. Dis. 186, 1522–1525 (2002).

  136. 136

    Kiechl, S. et al. Toll-like receptor 4 polymorphisms and atherogenesis. N. Engl. J. Med. 347, 185–192 (2002).

  137. 137

    Sheedy, F. J., Marinou, I., O'Neill, L. A. & Wilson, A. G. The Mal/TIRAP S180L and TLR4 G299D polymorphisms are not associated with susceptibility to, or severity of, rheumatoid arthritis. Ann. Rheum. Dis. 67, 1328–1331 (2008).

  138. 138

    Gewirtz, A. T. et al. Dominant-negative TLR5 polymorphism reduces adaptive immune response to flagellin and negatively associates with Crohn's disease. Am. J. Physiol. Gastrointest Liver Physiol. 290, G1157–G1163 (2006).

  139. 139

    Castiblanco, J. et al. TIRAP (MAL) S180L polymorphism is a common protective factor against developing tuberculosis and systemic lupus erythematosus. Infect. Genet. Evol. 8, 541–544 (2008).

  140. 140

    Khor, C. C. et al. A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nature Genet. 39, 523–528 (2007).

  141. 141

    Nejentsev, S. et al. Analysis of association of the TIRAP (MAL) S180L variant and tuberculosis in three populations. Nature Genet. 40, 261–262; author reply 262–263 (2008).

  142. 142

    Ramasawmy, R. et al. Heterozygosity for the S180L variant of MAL/TIRAP, a gene expressing an adaptor protein in the toll-like receptor pathway, is associated with lower risk of developing chronic chagas cardiomyopathy. J. Infect. Dis. 199, 1838–1845 (2009).

  143. 143

    Ferwerda, B. et al. Functional and genetic evidence that the Mal/TIRAP allele variant 180L has been selected by providing protection against septic shock. Proc. Natl Acad. Sci. USA 106, 10272–10277 (2009).

  144. 144

    Demirci, F. Y. et al. Association of a common interferon regulatory factor 5 (IRF5) variant with increased risk of systemic lupus erythematosus (SLE). Ann. Hum. Genet. 71, 308–311 (2007).

  145. 145

    Ferreiro-Neira, I. et al. Opposed independent effects and epistasis in the complex association of IRF5 to SLE. Genes Immun. 8, 429–438 (2007).

  146. 146

    Tewfik, M. A. et al. Polymorphisms in interleukin-1 receptor-associated kinase 4 are associated with total serum IgE. Allergy 64, 746–753 (2009).

  147. 147

    Day, N. et al. Interleukin receptor-associated kinase (IRAK-4) deficiency associated with bacterial infections and failure to sustain antibody responses. J. Pediatr. 144, 524–526 (2004).

  148. 148

    Picard, C. et al. Pyogenic bacterial infections in humans with IRAK-4 deficiency. Science 299, 2076–2079 (2003).

  149. 149

    Medvedev, A. E. et al. Distinct mutations in IRAK-4 confer hyporesponsiveness to lipopolysaccharide and interleukin-1 in a patient with recurrent bacterial infections. J. Exp. Med. 198, 521–531 (2003).

  150. 150

    Picard, C. et al. Inherited human IRAK-4 deficiency: an update. Immunol. Res. 38, 347–352 (2007).

  151. 151

    Dhiman, N. et al. Associations between SNPs in toll-like receptors and related intracellular signaling molecules and immune responses to measles vaccine: preliminary results. Vaccine 26, 1731–1736 (2008).

  152. 152

    Sheedy, F. J. et al. Negative regulation of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nature Immunol. 11, 141–147 (2010).

Download references

Acknowledgements

E.H. would like to thank the Health Research Board and L.A.J.O. thanks Science Foundation Ireland for financial support.

Author information

Correspondence to Luke A. J. O'Neill.

Ethics declarations

Competing interests

L.A.J.O is a cofounder of Opsona Therapeutics, which uses immune system research to develop new drugs and vaccines.

Related links

Related links

DATABASES

OMIM

actinic keratosis

inflammatory bowel disease

ClinicalTrials.gov

NCT00729053

NCT00633529

NCT00719199

NCT00251394

NCT00403052

NCT00091208

NCT00675727

NCT00728936

NCT00990938

NCT00823862

NCT00603811

NCT00688415

NCT00770003

NCT00999466

NCT00547014

NCT00334828

NCT00633477

FURTHER INFORMATION

Mologen AG's clinical development programe MGN-1703

Phase I clinical trial of AVE0675 in patients with allergy

OPN-401 development

Luke A. J. O'Neill's homepage

Glossary

Tumour necrosis factor.

(TNF). A pro-inflammatory cytokine involved in immune response. It induces apoptosis and inflammation.

MD-2

A cell surface molecule that is associated with TLR4. It is required for immune signalling in response to lipopolysaccharide.

Toll–interleukin-1 resistance (TIR) domain

A conserved intracellular domain of Toll and IL-1 families of receptors, which is also present in the adaptor molecules MYD88, MAL, TRIF and TRAM.

Interleukin-1 receptor-associated kinase 4

(IRAK4). A kinase that interacts with MYD88 and TRAF6 and is crucial for TLR signalling.

Nuclear factor-κB

(NF-κB). A transcription factor that is translocated to the nucleus following the stimuation of cell surface receptors by microbe-associated molecular patterns.

Type I interferons

A class of cytokines, produced by plasmacytoid dendritic cells, that includes interferon α and β.

Monophosphoryl lipid-A

(MPL). A non-toxic derivative of lipid-A from Gram-negative lipopolysaccharide.

Coley's toxin

A mixture of lipopolysaccharides and bacterial DNA products named after William Coley, who in 1893 first used dead bacteria to improve the survival of inoperable patients with cancer.

Regulatory T cells

A class of T cells that suppresses the immune response and prevents the development of autoimmune disorders.

Structure–activity relationship

A medicinal chemistry approach that involves the correlation of structural features with the activity of compounds in a given assay to improve potency and/or efficacy.

T-helper 1 cell (Th1) response

An immune response involved in cell-mediated immunity that is produced when dendritic cells interact with pre-T-helper cells to produce IFNγ, IL-1, IL-2 and TNF-β, and leads to the activation of macrophages.

CpG-based oligonucleotides

Oligonucleotides with cytosine–phosphate–guanosine-containing motifs that are found mainly in bacterial and viral DNA and that induce an immune response through activation of TLR9. There are three classes of CpG-oligonucleotides, CpG-A, CpG-B and CpG-C.

Immune modulatory oligonucleotides

(IMOs). DNA or RNA based oligonucleotides of varying length that are used to target TLR7, TLR8 or TLR9.

T-helper 2 cell (Th2) response

Part of the humoral immune response that helps B-cells produce IL-4, IL-5, IL-6, IL-9, IL-10 and IL-13, which evoke a strong antibody response and are required for the production of IgE. This leads to eosinophil and mast-cell accumulation and an allergic response.

Lipid-A

The biologically active part of LPS, its hydrophobic nature anchors LPS to the membrane.

Flagellin

A protein constituent of a bacterium's flagellum that specifically activates TLR5.

Ribavarin

An antiviral pro-drug that when metabolized resembles RNA purine molecules. It impedes DNA and RNA metabolism and interferes with viral replication. It is active against many viruses including influenza and hepatitis B.

CD80/86

A cell surface protein found on activated B-cells and monocytes that provides the necessary stimulation to prime T cells. When this complex binds to CTLA-4 expressed on the surface of T helper cells, the T-cell response is reduced.

Ectodomain of matrix protein 2

(M2e). A highly conserved region of the influenza A virus that consists of 23 amino acids of the M2 protein (the third integral membrane protein of the virus).

Lipid-IVa

A precursor in the biosynthetic pathway for lipopolysaccharide that acts as a TLR4 antagonist.

Systematic evolution of ligands by exponential enrichment

(SELEX). Also known as in vitro evolution. This process is used to produce either RNA or DNA oligonucleotides that specifically bind to a ligand. The process starts with a large library of oligonucleotides that are then exposed to the ligand. The process is repeated and the oligonucleotide sequence amplified until an aptamer that has a high affinity for the ligand is produced.

microRNAs

(miRNAs). Small 20–23 nucleotide non-coding RNA molecules that fine-tune gene expression by targeting specific messanger RNA.

Locked nucleic acid miRNA inhibitor

Nucleic acid analogues in which the ribose ring is 'locked' by a methylene bridge, resulting in increased thermal stability and discrimination with respect to target nucleic acids.

Ubiquitination

A post-translational modification involving 3 enzymes: E1 the ubiquitin-activating enzyme, E2 the ubiquitin-conjugating enzyme and E3 the ubiquitin protein ligase. Tagging a molecule with K48-linked ubiquitins targets it for degradation by the proteasome

Pellino3

A protein with E3 ubiquitin ligase activity that activates the p38 MAP kinase pathway to negatively regulate TLR signalling.

NF-κB essential modifier

(NEMO). The regulatory subunit of the IκB kinase complex that phosphorylates inhibitors of NF-κB, leading to their degradation and the translocation of NF-κB into the nucleus.

IκB kinase (IKK) complex

A complex that contains two catalytic subunits, IKKα and IKKβ, and the regulatory subunit NEMO that acts as a master regulator of NF-κB activation.

Inhibitors of apoptosis

(IAPs). Endogenous inhibitors of programmed cell death or apoptosis, which bind caspases and inhibit their activation.

Second mitochondria-derived activator of caspase

(SMAC). A protein that promotes cytochrome-c-dependent cell activation by eliminating IAP, which leads to cell apoptosis.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Hennessy, E., Parker, A. & O'Neill, L. Targeting Toll-like receptors: emerging therapeutics?. Nat Rev Drug Discov 9, 293–307 (2010). https://doi.org/10.1038/nrd3203

Download citation

Further reading